Post by Trinity College Dublin

Earlier this week we announced Trinity will host two Research Ireland-funded Rinn Research Centres (Rinn Quantum, and Rinn Advanced Therapies), and act as a coordinating institution for Rinn Artificial Intelligence. Today we put the spotlight on Rinn Advanced Therapies, which is focused on the development, biomanufacturing, and translation of personalised advanced cellular immune therapeutics (ACITs), which are expected to make up 10% of all medicines by 2035 and have wide ranging applications including in treating cancer and autoimmune diseases. The Centre, which brings together around 60 PIs, will link academia (Trinity; University of Galway; Maynooth University; University College Dublin; TU Dublin; University College Cork; and Royal College of Surgeons in Ireland (RCSI), with national organisations: NIBRT National Institute for Bioprocessing Research and Training; Irish Blood Transfusion Service; and the National Center for PharmacoEconomics (NCPE); and hospitals: The Mater, St. Vincent's University Hospital; University Hospital Galway; Children’s Healthcare Ireland; and St James's Hospital Dublin. Director, Prof. Sakis Mantalaris from TCD School of Pharmacy & Pharmaceutical Sciences and NIBRT, said: “Ireland has a globally renowned pharmaceutical manufacturing industry but has fallen behind in ACIT research and clinical translation. RINN Advanced Therapies will enable a vein-to-vein innovation ecosystem to discover, manufacture and implement ACITs, and will put patients and society at the core ensuring that access, affordability, and availability are addressed early. RINN Advanced Therapies’ novelty will be in the implementation of personalised Quality by Design (pQbD), by integrating clinical outcomes with the design and biomanufacturing of the cell product to ultimately enable personalised ACITs, beyond precision.” “Our centre aspires to lead Ireland into the ‘fifth Industrial Revolution’, which focuses on the individual, by delivering a novel, personalised immune cell therapies-data-biomanufacturing nexus. Now is the time to come together and work hard to deliver the first Irish ACIT.” Co-Director, Prof. Owen Smith, School of Medicine, Trinity College Dublin, and Molecular Medicine Ireland, added: “Trinity, alongside its partner institutions, has made a solemn commitment through Rinn Advanced Therapies to develop and manufacture personalised Advanced Cellular Immune Therapeutics, a transformative class of therapies with the potential to redefine how we treat cancer and a broad range of autoimmune diseases. “Rinn Advanced Therapies is not simply a research programme; it is the foundation of an entirely new therapeutic ecosystem for Ireland and beyond. This is Ireland staking its claim at the frontier of a global medical revolution and in doing so, we will not be watching this revolution from the sidelines; we will be shaping it, for our patients and for generations to come.” #TrinityResearch #rinnnetwork